| Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR-Mutant NSCLC X Le, S Puri, MV Negrao, MB Nilsson, J Robichaux, T Boyle, JK Hicks, ... Clinical Cancer Research 24 (24), 6195-6203, 2018 | 342 | 2018 |
| MYC drives temporal evolution of small cell lung cancer subtypes by reprogramming neuroendocrine fate AS Ireland, AM Micinski, DW Kastner, B Guo, SJ Wait, KB Spainhower, ... Cancer cell 38 (1), 60-78. e12, 2020 | 292 | 2020 |
| Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology AKP Ganti, BW Loo, M Bassetti, C Blakely, A Chiang, TA D'Amico, ... Journal of the National Comprehensive Cancer Network 19 (12), 1441-1464, 2021 | 184 | 2021 |
| Combination checkpoint inhibitors for treatment of non-small-cell lung cancer: an update on dual anti-CTLA-4 and anti-PD-1/PD-L1 therapies S Puri, M Shafique Drugs in context 9, 2020 | 51 | 2020 |
| 315O Sotorasib in combination with panitumumab in refractory KRAS G12C-mutated colorectal cancer: Safety and efficacy for phase Ib full expansion cohort Y Kuboki, R Yaeger, MG Fakih, JH Strickler, T Masuishi, EJ Kim, ... Annals of Oncology 33, S680-S681, 2022 | 47 | 2022 |
| Physician–pharmacist collaboration for oral chemotherapy monitoring: insights from an academic genitourinary oncology practice LM Holle, S Puri, JM Clement Journal of Oncology Pharmacy Practice 22 (3), 511-516, 2016 | 41 | 2016 |
| Systemic and radiation therapy approaches for locally advanced non–small-cell lung cancer KA Higgins, S Puri, JE Gray Journal of Clinical Oncology 40 (6), 576-585, 2022 | 30 | 2022 |
| Locally advanced, unresectable non-small cell lung cancer S Puri, A Saltos, B Perez, X Le, JE Gray Current oncology reports 22, 1-10, 2020 | 24 | 2020 |
| Immune checkpoint inhibitors in early-stage and locally advanced non-small cell lung cancer S Puri, M Shafique, JE Gray Current Treatment Options in Oncology 19, 1-17, 2018 | 24 | 2018 |
| Prediction of chemotherapy-induced nausea and vomiting from patient-reported and genetic risk factors S Puri, KA Hyland, KC Weiss, GC Bell, JE Gray, R Kim, HY Lin, ... Supportive Care in Cancer 26, 2911-2918, 2018 | 24 | 2018 |
| The forgotten disease: bilateral lemierre’s disease with mycotic aneurysm of the vertebral artery T Gupta, K Parikh, S Puri, S Agrawal, N Agrawal, D Sharma, L DeLorenzo The American journal of case reports 15, 230, 2014 | 23 | 2014 |
| Cabozantinib (C) plus atezolizumab (A) or C alone in patients (pts) with advanced non–small cell lung cancer (aNSCLC) previously treated with an immune checkpoint inhibitor … JW Neal, A Santoro, S Viteri, S Ponce Aix, B Fang, FL Lim, RD Gentzler, ... Journal of Clinical Oncology 40 (16_suppl), 9005-9005, 2022 | 21 | 2022 |
| The role of gut microbiome in modulating response to immune checkpoint inhibitor therapy in cancer AR Naqash, AJ Kihn-Alarcón, C Stavraka, K Kerrigan, SM Vareki, ... Annals of Translational Medicine 9 (12), 2021 | 21 | 2021 |
| A definitive prognostication system for patients with thoracic malignancies diagnosed with coronavirus disease 2019: an update from the TERAVOLT registry JG Whisenant, J Baena, A Cortellini, LC Huang, GL Russo, L Porcu, ... Journal of Thoracic Oncology 17 (5), 661-674, 2022 | 16 | 2022 |
| A real-world analysis of the use of systemic therapy in malignant pleural mesothelioma and the differential impacts on overall survival by practice pattern K Kerrigan, Y Jo, J Chipman, B Haaland, S Puri, W Akerley, S Patel JTO Clinical and Research Reports 3 (3), 100280, 2022 | 14 | 2022 |
| Allogeneic hematopoietic cell transplantation is potentially curative in mantle cell lymphoma: results from a single institution study JD Sandoval-Sus, R Faramand, J Chavez, S Puri, P Parra, L Sokol, ... Leukemia & lymphoma 60 (2), 309-316, 2019 | 14 | 2019 |
| Is it time to implement adjuvant targeted therapy in EGFR-mutant non–small-cell lung cancer? AA Kulkarni, AR Naqash, S Puri, R Dienstmann JCO Precision Oncology 5, 2021 | 12 | 2021 |
| Pericardial synovial sarcoma: challenges in diagnosis and management P Phatak, J Khanagavi, WS Aronow, S Puri, Y Yusuf, C Puccio F1000Research 3, 2014 | 12 | 2014 |
| Safety and activity of immune checkpoint inhibitors in people living with HIV and cancer: A real-world report from the cancer therapy using checkpoint inhibitors in people … T El Zarif, AH Nassar, E Adib, BG Fitzgerald, J Huang, TH Mouhieddine, ... Journal of Clinical Oncology 41 (21), 3712-3723, 2023 | 11 | 2023 |
| A phase 1b study of sotorasib, a specific and irreversible KRASG12C inhibitor, in combination with other anticancer therapies in advanced colorectal cancer (CRC … DS Hong, R Yaeger, Y Kuboki, T Masuishi, MA Barve, GS Falchook, ... Journal of Clinical Oncology 40 (4_suppl), TPS214-TPS214, 2022 | 11 | 2022 |
Jagadish Khanagavi MD, FACP, FAC...University of CincinnatiVerified email at uc.edu
